Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial

Abstract Background This study aimed to evaluate the efficacy and safety of camrelizumab, an anti-PD-1 antibody, combined with either chemotherapy or apatinib, a VEGFR-2 inhibitor, as neoadjuvant treatment for stage IIA–IIIA NSCLC. Methods This prospective, multicenter, dual-arm, non-randomized phas...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuyu Ji, Zhenxin Sheng, Dongliang Bian, Minwei Bao, Kaiqi Jin, Wentian Zhang, Xinsheng Zhu, Fenghuan Sun, Haoran Xia, Han Zhang, Ziyun Shen, Huansha Yu, Lele Zhang, Jie Huang, Zhang Peng, Nan Song, Haifeng Wang, Biyun Qian, Yuming Zhu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Medicine
Subjects:
Non-small-cell lung cancer
Neoadjuvant
Camrelizumab
Apatinib
Major pathologic response
Online Access:https://doi.org/10.1186/s12916-025-04250-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12916-025-04250-4

Similar Items